Kleo Pharmaceuticals, a New Haven-based immune-oncology company, was named Murphyâs Innovator of the Month on Aug. 7 by U.S. Sen. Chris Murphy.
Kleo was recognized for its advancement in the development of innovative bispecific compounds designed to emulate or enhance the activity of biologics to directly enlarge a patientâs immune system to target and destroy harmful cells.
âKleo Pharmaceuticals is proof that Connecticut is a major hub for innovation. Their cutting-edge research and approach is being used to create products that will make a difference in the lives of people suffering from cancer. Iâm happy to recognize Kleo as my âInnovator of the Monthâ for their amazing work and commitment to Connecticut,â said Murphy.
Kleo will be advancing several drug candidates based on its proprietary technology platform and has partnered with Tokyo-based biopharmaceutical company PeptiDream to create a proprietary immune-oncology product to treat multiple myeloma.
âKleo is pleased to accept Senator Murphyâs award, and we are committed to the New Haven community and to helping grow Connecticutâs biopharmaceutical sector,â said Dr. Douglas Mansion, the CEO of Kleo.
After four years, the 18-person company will expand to a new office space in New Haven and plans a 30 percent increase in staff.
âOur company has come a long way, and we are honored to be recognized for our accomplishments along with other emerging companies in Connecticut. In the last several months, we have worked diligently to redesign our office space and labs, remodel our website and push forward our development of next-generation immune-oncology drugs,â said Mansion.